Jupiter Neurosciences prices $2.0 million registered direct offering at $6.50 per share

Jupiter Neurosciences, Inc. (NASDAQ: JUNS), described in its press release as a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation¹, priced a registered direct offering on August 21, 2026. Under the deal, the company agreed to issue and sell 307,692 shares of common stock at a price of $6.50 per share, for aggregate gross proceeds of approximately $2.0 million before deducting placement agent fees and related offering expenses.¹

D. Boral Capital LLC is serving as the exclusive placement agent for the offering.¹ The company has agreed to compensate the placement agent through a cash fee equal to 7.0% of the gross proceeds from the sale of the shares, plus reimbursement of reasonable out-of-pocket expenses including legal fees not to exceed $75,000.²

According to the related prospectus supplement, the closing is set for the same date the deal was announced to close, and the company said delivery of the securities is expected to be made on or about August 24, 2026.² The shares are being sold under an existing shelf registration, which was declared effective by the SEC on April 24, 2026.¹

Jupiter said it expects to net roughly $1.74 million from the offering after fees and expenses, to be used for working capital and other general corporate purposes.²

The filings also flagged financial strain. Jupiter's auditor included an explanatory paragraph relating to the company's ability to continue as a going concern in its audit report covering the fiscal years ended December 31, 2025 and 2024,² a conclusion the company attributed to historical recurring losses from operations and negative cash flows from operations, as well as dependence on private equity and other financings.² The company stated that its current cash balance is not sufficient to fund planned operations for the next twelve months, and it called this offering an important component of its financing plan.²